header
Image from OpenLibrary

Comparative study of different preoperative statin regimens for the prevention of post coronary artery bypass graft (CABG) surgery cardiovascular adverse events / Aya Gamal Aly Elmarsafawi ; Supervised Nirmeen Sabry , Maggie Abbassi , Hassan Elsawy

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Aya Gamal Aly Elmarsafawi , 2017Description: 120 P. ; 25cmOther title:
  • دراسة لمقارنة نظم عالجية مختلفة من الستاتين قبل جراحة تحويل مسار الشريان التاجى لمنع الأحداث السلبية على القلب و الأوعية الدموية [Added title page title]
Subject(s): Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics Summary: Background: Coronary artery bypass grafting (CABG) offers an effective palliative treatment for Ischemic heart disease (IHD) patients. This is always challenged by the deleterious cardiac and non-cardiac complications afterwards. Statins have proven effective and safe at reducing the risk of some of these complications. Yet, there is no established optimal regimen for statin use. The dosing regimen varies among hospitals and is mostly based on clinicians{u2019} experience. Aim: Comparing different perioperative statin regimens for the prevention of post CABG adverse events. Methods: This prospective clinical trial was conducted at the cardiothoracic surgical units at the national heart institute, Cairo, Egypt. Ninety four patients scheduled for elective, isolated on- or off-pump CABG at were assigned to one of 3 treatment groups; group I (80 mg Atorvastatin/day for 2 days preoperatively (N=37)), group II (40 mg atorvastatin/day for 5-9 days preoperatively (N=29) or group III (80 mg atorvastatin/day for 5-9 days preoperatively (N=28)). The corresponding preoperative regimens were restarted postoperatively (post-op) when patients were able to take the medication orally and were continued for one month. Cardiac troponin I (TnI), creatine kinase (CK-MB) and C-reactive protein (CRP) were assayed preoperatively and at 8, 24, 48 hours postoperatively, and at discharge. Time course of changes of marker levels across these time points were compared among the three groups. The incidence of post-op major adverse cardiac and cerebrovascular events (MACCE) was assessed including; 30-day all-cause mortality, myocardial infarction, atrial fibrillation (AF), ventricular tachycardia/ventricular fibrillation, stroke and target-vessel revascularization
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Date due Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.08.08.M.Sc.2017.Ay.C (Browse shelf(Opens below)) Not for loan 01010110073362000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.08.08.M.Sc.2017.Ay.C (Browse shelf(Opens below)) 73362.CD Not for loan 01020110073362000

Thesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics

Background: Coronary artery bypass grafting (CABG) offers an effective palliative treatment for Ischemic heart disease (IHD) patients. This is always challenged by the deleterious cardiac and non-cardiac complications afterwards. Statins have proven effective and safe at reducing the risk of some of these complications. Yet, there is no established optimal regimen for statin use. The dosing regimen varies among hospitals and is mostly based on clinicians{u2019} experience. Aim: Comparing different perioperative statin regimens for the prevention of post CABG adverse events. Methods: This prospective clinical trial was conducted at the cardiothoracic surgical units at the national heart institute, Cairo, Egypt. Ninety four patients scheduled for elective, isolated on- or off-pump CABG at were assigned to one of 3 treatment groups; group I (80 mg Atorvastatin/day for 2 days preoperatively (N=37)), group II (40 mg atorvastatin/day for 5-9 days preoperatively (N=29) or group III (80 mg atorvastatin/day for 5-9 days preoperatively (N=28)). The corresponding preoperative regimens were restarted postoperatively (post-op) when patients were able to take the medication orally and were continued for one month. Cardiac troponin I (TnI), creatine kinase (CK-MB) and C-reactive protein (CRP) were assayed preoperatively and at 8, 24, 48 hours postoperatively, and at discharge. Time course of changes of marker levels across these time points were compared among the three groups. The incidence of post-op major adverse cardiac and cerebrovascular events (MACCE) was assessed including; 30-day all-cause mortality, myocardial infarction, atrial fibrillation (AF), ventricular tachycardia/ventricular fibrillation, stroke and target-vessel revascularization

Issued also as CD

There are no comments on this title.

to post a comment.